Europe Branded Generics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Europe represents one of the largest regional markets for branded generics globally, reflecting the region's mature pharmaceutical systems and high generic penetration rates. Within the broader European generic drug market, branded generics account for the majority share of volume and value. The market's size of approximately $42.28 billion in 2025 positions it as a cornerstone of the region's cost-containment strategy.

• •Estimated market size of $42.28 billion in 2025
• •Forecast compound annual growth rate of approximately 5.9% per year
• •Branded generics hold a dominant share within Europe's wider generic drugs market

Patent expirations on blockbuster originator drugs continue to create substitution opportunities for branded generic manufacturers. National reimbursement systems and health technology assessments across the EU favor lower-cost alternatives, accelerating uptake. An aging European population and the rising prevalence of chronic conditions such as cardiovascular disease, diabetes, and respiratory illness sustain long-term demand.

• •Ongoing patent cliffs across major therapeutic categories
• •Payer and government pressure to contain drug expenditure
• •Demographic aging and chronic disease burden expanding the patient base

The market is commonly segmented by therapeutic area, formulation, and distribution channel, with central nervous system, cardiovascular, and anti-infective agents among the leading categories. Western European countries, particularly Germany, the United Kingdom, France, Italy, and Spain, account for the bulk of regional revenue, while Central and Eastern Europe offer higher growth potential as generic penetration rises.

• •Germany and the UK are among the largest national markets in the region
• •Central nervous system and cardiovascular therapies lead by therapeutic class
• •Retail pharmacies and hospital channels dominate distribution

What are the recent trends and outlook?

Biosimilars and complex generics are emerging as adjacent growth areas, with manufacturers investing in higher-value product categories. Digital health integration and value-added services are increasingly being bundled with branded generics to differentiate offerings. Looking ahead, the market is expected to continue expanding at around 5-6% annually through the early 2030s, supported by policy support for generic substitution and sustained patent expiries.

• •Increasing investment in complex generics and biosimilars
• •Policy frameworks across the EU continue to encourage generic substitution
• •Steady mid-single-digit annual growth projected through the early 2030s